论文信息 - The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial - 字舞流文

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

A. Roberts | S. Opat | C. Tam | M. Gilbertson | J. Seymour | D. Ritchie | L. Luo | L. Xue | A. Grigg | Lai Wang | M. Anderson | E. Hedrick | Carmen Dicorleto | M. Ku | Jianxin Yang | Belinda Dimovski | Stephen Samuel Opat